Sarepta Therapeutics, Inc. Securities Litigation (2019)

If you purchased a significant amount of shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT), you have certain options. Investors should register for updates.


Lawsuit Overview

Defendant:Sarepta Therapeutics, Inc.
Date Filed:August 30th, 2019
Sector:Health Care
Industry:Major Pharmaceuticals
Class Start Date:September 6th, 2017
Class End Date:August 19th, 2019

According to the Complaint, Sarepta focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. Sarepta's products pipeline includes, among other drug candidates, golodirsen for the treatment of duchenne muscular dystrophy.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding Sarepta's business, operational and compliance policies. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) golodirsen posed significant safety risks to patients; (ii) consequently, the NDA package for golodirsen's accelerated approval was unlikely to receive FDA approval; and (iii) as a result, Sarepta's public statements were materially false and misleading at all relevant times.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for Sarepta Therapeutics, Inc.

First Identified Complaint

Andrew Salinger, et al. v. Sarepta Therapeutics, Inc., et al.

Date Filed:August 30th, 2019
Class Period Start:September 6th, 2017
Class Period End:August 19th, 2019
First Identified Complaint Filings
#Document TitleFiling Date